WO2023052971 - AUTOMATED SYNTHESIS OF POLYMERIC DUAL DRUGS
National phase entry:
Publication Number
WO/2023/052971
Publication Date
06.04.2023
International Application No.
PCT/IB2022/059149
International Filing Date
27.09.2022
Title **
[English]
AUTOMATED SYNTHESIS OF POLYMERIC DUAL DRUGS
[French]
SYNTHÈSE AUTOMATISÉE DE MÉDICAMENTS DOUBLES POLYMÈRES
Applicants **
SONY GROUP CORPORATION
1-7-1 Konan, Minato-ku
Tokyo, Tokyo 108-0075, JP
Inventors
MATRAY, Tracy
1730 N. First St.
San Jose, California 95112, US
VANBRUNT, Michael
1730 N. First St.
San Jose, California 95112, US
MCCUTCHEON, John Michael
1730 N. First St.
San Jose, California 95112, US
Priority Data
63/250,913
30.09.2021
US
63/253,071
06.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4303 | |
| EPO | Filing, Examination | 58395 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 19760 |
Total: 83651 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
, l, m, n, p, and q are as defined herein. Additional compound, methods of preparation, pharmaceutical compositions, and methods of treatment related to compounds of Structure (I) are also provided.[French]
, 1, m, n, p, et q sont tels que définis dans la description. L'invention concerne également des composés supplémentaires, des procédés de préparation, des compositions pharmaceutiques et des méthodes de traitement associés à des composés de structure (I).